Competing folate receptor-targeting projects have recorded one failure after another, but Sutro scores a phase I win.
Lilly and Roche bask in the reflected glow of aducanumab's benign briefing documents.
The FDA will have a busy November, with decisions due for Bristol, Sanofi and Y-mabs, among others.
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.